Anti-PRG2 Polyclonal Antibody for WB, IF/ICC, IHC-P, ELISA - P13727

Core Product Specifications and Parameters

Biological Background: PRG2 Function and Localization

• PRG2 (bone marrow proteoglycan, also known as eosinophil major basic protein, BMPG, MBP1) is a cytotoxin and helminthotoxin. It induces non-cytolytic histamine release from human basophils and participates in antiparasitic defense and immune hypersensitivity reactions.
• The proform of PRG2 acts as a proteinase inhibitor, reducing the activity of pregnancy-associated plasma protein A (PAPPA).
• PRG2 is a secreted protein localized to cytoplasmic vesicles and secretory vesicles.
• Tissue expression: PRG2 is detected in plasma and urine (at protein level) (PubMed:25326458, PubMed:36213313, PubMed:37453717). It is also detected in placenta (PubMed:32337544), with high levels of the proform in placenta and pregnancy serum. In placenta, it localizes to X cells of septa and anchoring villi. Lower levels are found in kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, and colon. Related references: PMID:25326458, PMID:36213313, PMID:37453717, PMID:32337544
• PRG2 is a heparin-binding proteoglycan with a lectin domain. It undergoes post-translational modifications including glycosylation, tyrosine nitration, and disulfide bond formation.
• The protein exhibits antimicrobial and antibiotic activity, contributing to innate immunity.
• Alternative splicing produces multiple isoforms of PRG2.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide from amino acids 100–200 of human PRG2. For cross-species applications, verify sequence homology in the target species (reactivity is confirmed for human, mouse, and rat).
• For western blot (WB), the anticipated band is approximately 25 kDa. Prepare appropriate positive and negative controls using cell lines or tissues with known PRG2 expression.
• In immunohistochemistry (IHC-P) and immunofluorescence (IF/ICC), optimize antigen retrieval methods and antibody dilution using a known positive tissue (e.g., placenta, bone marrow).
• For ELISA, consider direct or capture assay formats and validate coating conditions with recombinant PRG2 or native protein from biological samples.
• The polyclonal nature may yield higher sensitivity but requires careful titration to minimize background; test multiple dilutions in the relevant sample system.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio connects diagnostic developers and researchers with a comprehensive portfolio of IVD raw materials, including validated antibody pairs, monoclonal and polyclonal antibodies, bulk ancillary reagents, and sourcing for rare targets. Our supply chain capabilities support the entire diagnostic development workflow, from early-stage research to commercial manufacturing. For anti-PRG2 antibodies and other immune-related raw materials, trust CamelBio to deliver consistent quality and reliable supply.